In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VLST Corp.

Latest From VLST Corp.

Deals Shaping The Medical Industry, October 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

VLST expands into oncology with clinical-stage Pfizer antibody

The private US biotechnology firm VLST has added oncology to its list of targeted disease areas, on top of autoimmune and inflammatory disorders, by in-licensing the anti-CD40 monoclonal antibody CP-870,893 from Pfizer, which has taken a 5% equity position in VLST and is entitled to milestone payments from the development programme.

Cancer Orthopedics

Oncothyreon appoints new CFO

The US biotechnology company Oncothyreon has appointed Julie Eastland chief financial officer and vice-president of corporate development. Ms Eastland previously served as CFO and vice-president of finance and operations at VLST, a privatelyheld biotech company, as well as finance positions at Dendreon, Amgen and Encore Media Group.


2010 Scrip 100 - A sense of venture

Corporate venture funds are taking an increasingly high-profile role in biotech financing deals. Eva Jack and Dr Maggie Flanagan LeFlore, managing directors of MedImmune Ventures, explain to Pete Chan why their drivers are both financial and strategic.

Cardiovascular Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • VLST Corp.
  • Senior Management
  • Martin A Simonetti, Pres. & CEO
    Teresa M Foy, PhD, CSO
    Brian Blackman, VP, Fin. & Admin.
    Rob Myers, VP, Corp. Dev.
  • Contact Info
  • VLST Corp.
    Phone: (206) 262-5500
    307 Westlake Ave. N.
    Ste. 300
    Seattle, WA 98109